Table 3

Synovial fluid T-cell expression of differentiation and activation markers in disease subgroups of patients with juvenile idiopathic arthritis
SF T cells
 Oligo
 Poly
 JPsA
 B27-
 B27+
 ANA-
 ANA+
 APR hi
 APR lo
 Drugs+
 Drugs-
CD69
 10.1
 15.8
 13.4
 14.3
 11.8
 13.1
 15.8
 14.4
 8.9
 14.6
 14.3
CD25
 3.9
 3.9
 4.4
 4.2
 3.6
 4.2
 3.9
 4.0
 4.2
 4.2
 4.0
CD71
 3.5
 3.4
 4.5
 3.7
 3.5
 3.7
 3.6
 3.8
 3.2*
 3.7
 3.7
HLA-DR
 13.1
 33.5
 30.2
 20.5
 11.8
 18.9
 47.4
 16.0
 19.6
 19.2
 30.2
CD45RO
 74.6
 78.8
 81.1
 77.8
 80.1
 76.4
 78.9
 78.9
 77.8
 77.3
 79.0
CD45RB
 78.4
 88.8
 92.2
 89.4
 106.7
 88.3
 89.8
 85.1
 89.8
 92.2
 69.9

All values represented as median fluorescence intensity (MFI) except CD45RO, which is represented as median % positive. Patients were grouped according to disease subgroup (oligoarthritis, polyarthritis or psoriatic arthritis), and expression or absence of HLA-B27, ANA, a high or low acute-phase response (high: erythrocyte sedimentation rate >20 or C-reactive protein >5), and whether they had received intra-articular triamcinolone hexacetonide earlier in their disease process (drugs+ versus drugs-). There was a statistically significant difference between those groups of patients with a high or low APR (*P < 0.05). ANA = antinuclear antibodies; APR = acute-phase response; hi = high; lo = low; JPsA = juvenile psoriatic arthritis; Oligo = oligoarthritis; Poly = polyarthritis.

Black et al. Arthritis Res 2002 4:177   doi:10.1186/ar403

Open Data